GlassScriptPhysician profile
Marat L Reyzelman
NPI 1255516019
$18,254.17
in general payments reported to CMS, 2019-2025
63 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,755 · 2020: $1,167 · 2021: $2,033 · 2022: $1,325 · 2023: $1,635 · 2024: $8,593 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,865 · Food and Beverage: $3,616 · Travel and Lodging: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,865.00 |
| Food and Beverage | $3,616.02 |
| Travel and Lodging | $1,492.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $7,498.39 | 2024 | |
| Abbvie INC. | $1,484.00 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $790.47 | 2021 | |
| Novartis Pharmaceuticals Corporation | $458.17 | 2019-2024 | |
| Pfizer INC. | $450.88 | 2022-2025 | |
| Celgene Corporation | $424.98 | 2021-2025 | Zeposia |
| Amgen INC. | $420.72 | 2019-2024 | Uplizna, Aimovig |
| Allergan, INC. | $413.36 | 2019-2022 | |
| Ucb, INC. | $405.03 | 2019-2024 | Rystiggo, Briviact |
| Emd Serono, INC. | $334.17 | 2019-2025 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $321.99 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $316.42 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $298.03 | 2019-2023 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $270.86 | 2019-2022 | |
| Neurelis, INC. | $253.41 | 2020-2023 | Valtoco |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marat Reyzelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.